NL-OMON22166招募中不适用
Safety and efficacy of the addition of IMM-101 (Heat-Killed Whole Cell Mycobacterium obuense) to standard stereotactic radiotherapy in locally advanced pancreatic cancer patients. (LAPC-2 trial)
Erasmus MC, Surgery department0 个研究点目标入组 38 人开始时间: 待定最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 38
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Histologically confirmed pancreatic cancer, as indicated by a definite cytology report.
- •Tumor considered locally advanced after diagnostic work-up including CT-imaging, using the DPCG criteria for locally advanced disease and diagnostic laparoscopy.
- •Age > 18 years and < 75 years.
- •WHO performance status of 0 or 1.
- •ASA classification I or II.
- •No evidence of metastatic disease.
- •Largest tumor size < 7 cm x 7 cm x 7 cm.
- •Normal renal function (Creatinine = 30 ml/min).
- •Normal liver tests (bilirubin < 1.5 times normal*; ALAT/ASAT < 5 times normal).
- •Normal bone marrow function (WBC > 3.0 x 10e9/L, platelets > 100 x 10e9/L and hemoglobin > 5.6 mmol/l).
- •Ability to wear an Actiwatch device on non-dominant arm.
- •Effective contraceptive methods.
- •Written informed consent.
- •* If bilirubin is higher than 35 umol/L placement of a metal biliary stent is mandatory.
排除标准
- •Prior radiotherapy, chemotherapy other than FOLFIRINOX or pancreatic resection.
- •Current or previous treatment with immunotherapeutic drugs.
- •Previous allergic reaction to any mycobacterial product.
- •Prolonged systemic corticosteroid or immunosuppressant medication use (i.e. >2 weeks).
- •Lymph node metastases from primary tumor outside the field of radiation.
- •Second primary malignancy except in situ carcinoma of the cervix, adequately treated non-melanoma skin cancer, or other malignancy treated at least 5 years previously to diagnosis of pancreatic cancer and without evidence of recurrence.
- •Pregnancy, breast feeding.
- •Serious concomitant systemic disorders that would compromise the safety of the patient or his/her ability to complete the study, at the discretion of the investigator.
- •An active autoimmune disease that has required systemic treatment in past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
- •Diagnosis of immunodeficiency or receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the planned first dose of the study. The use of physiologic doses of corticosteroids may be approved after consultation with the Sponsor.
- •Known history of Human Immunodeficiency Virus (HIV) (HIV-1/2 antibodies).
- •Known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA [qualitative] is detected).
- •Live virus vaccine within 30 days of planned start of trial treatment.
- •Use of herbal remedies, including traditional Chinese herbal products (e.g., mistletoe).
研究者
相似试验
进行中（未招募）
1 期
Safety and efficacy of adding immunotherapy to the standard of care for locally advanced pancreatic cancer patients (LAPC-2 trial).EUCTR2019-000216-29-NLErasmus MC38
招募中
2 期
Safety and efficacy of the addition of IMM-101 Heat-Killed Whole Cell Mycobacterium obuense to standard stereotactic radiotherapy in locally advanced pancreatic cancer patients (LAPC-2 trial).NL-OMON49825Erasmus MC, Universitair Medisch Centrum Rotterdam38
进行中（未招募）
1 期
Safety and efficacy of adding immunotherapy combined with stereotactic radiotherapy in patients with limited metastatic pancreatic cancer(MEPANC-1)EUCTR2020-003945-13-NLErasmus MC100
招募中
2 期
Safety and efficacy of IMM-101 combined with stereotactic radiotherapy in patients with limited MEtastatic PANcreatic Cancer (MEPANC-1)metastatic pancreatic cancerpancreatic ductal adenocarcinoma10015674NL-OMON54853Erasmus MC, Universitair Medisch Centrum Rotterdam100
尚未招募
不适用
Safety and efficacy of IMM-101 combined with stereotactic radiotherapy in patients with limited MEtastatic PANcreatic Cancer (MEPANC-1)limited metastatic pancreatic cancerNL-OMON28039Erasmus MC100